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Editorial
Precision Spine Care: A New Era of
Discovery, Innovation, and Global Impact
Currently, government resources and initiatives, such as the
White House Precision/Personalized Medicine platform and
large-scale biobank cohorts located in Asia, Europe, and the
United States focusing on big data biometrics (eg, genetics,
blood biomarkers, imaging, tissue, and clinical profiles) have
declared the urgent need for more precise medical care on an
unprecedented level to improve health care utilization and
patient outcomes. As such, we have now entered an era of
“precision” medical care. However, such a platform has largely
focused on cardiovascular disease, diabetes or cancer whereby
targeted therapeutic drugs based on patient profiling and
genetic variation have dramatically improved patient outcomes
and led to more cost-effectiveness.1 Although such platforms
have seen substantial success, the health care community has to
date overlooked the more debilitating disorders of the muscu-
loskeletal system, in particular as they relate to the spine.
According to the recent Global Burden of Disease Study, low
back pain (LBP) is the world’s most disabling condition, affect-
ing every population worldwide.2 Individuals with LBP have
noted decreased daily function, diminished quality of life, work
disability, and psychological distress.3 Studies have even noted
that individuals with chronic LBP have significant loss of brain
tissue that can affect cognitive function.4 Such pain is associated
with tremendous socioeconomic and health-care consequences.
Indirect and direct costs related to the treatment of LBP are
estimated to be approximately US$90 billion per year in the
United States with similar adjusted rates in other countries
worldwide.5 Nonetheless, proper diagnosis of LBP and identifi-
cation of pain mechanisms are questionable, outcomes of LBP
treatments are often tenuous and have been criticized, and prog-
nostication potential of various pain and disability dimensions as
well as management options have limitations. As a result, such
limitations have led to increased health care costs to the patient
and medical provider with often unsatisfactory patient outcomes.
In fact, spine specialists have been often challenged by the pop-
ular press, patients, and insurance providers globally because of
their frequently poor outcomes in treating patients with LBP.
Importantly, although numerous generalized protocols/algo-
rithms and guidelines for the treatment of LBP have been pro-
posed, these often fail to account for more “personalized” or
“precise” patient variation with regards to lifestyle, occupation,
underlining systemic conditions (eg, patient psychological pro-
file, blood chemistry/inflammatory biomarkers, genetics, etc),
patterns of imaging findings and other biometrics that have tre-
mendous potential in the management of LBP.6,7 For example,
we now know that specific pain genes may predict outcomes
following treatments for various spine disorders, and that such
genetic make-up provides further insight into pain intensity and
disability.8 Such systemic conditions and others have been found
to assist in identifying subtypes of pain that may be more amen-
able to various treatments, understanding patients’ pain thresh-
olds and perceptions, predicting outcomes, and further
identifying specific pain generators to assist in more tailor-
made or “precise” treatments.9 In fact, the same applies for other
spine conditions, whose occurrence, diagnosis, treatments, and
outcomes remain uncertain. For example, disc degeneration is a
common condition that affects individuals in every population.10
It still remains speculative why an individual develops disc
degeneration and overall different patterns of spinal changes.
Nonetheless, it has been a long-held belief that severe disc
changes may lead to pain in the low back or in the neck.11
However, not everyone who has disc degeneration is painful and
not every individual who has neck pain or LBP has severe disc
changes.12 Moreover, it remains a mystery as to who may prog-
ress to more severe forms of disc degeneration or who may
develop disc herniations and resolution of such conditions.
Regenerative therapies to treat disc degeneration have taken
center stage in the past decade. However, outcomes in human
subjects have remained short from stellar with often unsatisfac-
tory results. It remains unknown as to which patients may benefit
from such therapy and/or predict their outcomes with some cer-
tainty.13 In fact, regenerative biologics have yet to account for
the overall personalized profile of an individual to fine-tune
therapeutic dose, approach, and effectiveness to not only regen-
erate the disc but also to delay progression or protect its integrity.
The above not only applies to “de novo” degeneration, but it is
also relevant to degeneration/disease that may develop adjacent
to an operated disc. Such a condition may also necessitate future
conservative treatment (eg, physical therapy, medication, injec-
tions, etc) or surgery. However, who may be more prone to
develop such conditions, how to prevent and manage them, and
predict their outcomes is poorly understood. Furthermore, spinal
deformities, such as adolescent idiopathic scoliosis, can be life-
altering conditions. Who may progress to more severe deformity
and additional comorbidities, respond to conservative treatment
(eg, bracing) or obtain optimal surgical outcomes continues to
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perplex the spine specialist. Preventative measures for such
patients continue to remain speculative. Moreover, in general,
not all individuals who undergo conservative management for
various spine conditions have favorable outcomes. In other
words, the “one-size-fits-all” guideline- and protocol-based
approach to treating patients with spine-related conditions, is
no longer adequate. More precise approaches to identifying the
“right” patient for the “right” treatment as well discovering/
developing targeted therapies based on more detailed or perso-
nalized patient profiling is needed. Understanding with certainty
in advance as to who may have a good or bad response to a
treatment would be invaluable to all stakeholders.
To combat the massive global burden of LBP and other
spine-related conditions, health care systems must develop
coherent policies with more “precision-based” management
algorithms to maximize proper diagnosis, preventative mea-
sures, tailor novel therapeutics, predict outcomes with more
certainty (eg, risk assessment, predictive modeling), and over-
all improve patient outcomes and function. Precision medi-
cine strategies aim to have treatments tailored specifically to
the patients’ individual needs based on their genetic, immune
system status, and overall systemic biomarker omics profile
as well as additional phenotype information (eg, imaging,
lifestyle) with the goal of improving outcomes and reducing
adverse reactions via a wholistic fingerprint and oftentimes
big data approach. This may lead to improved quality of life
for patients, reduction in noneffective treatments and more
cost-effective outcomes, translating into more productive
societies.
Prioritization of research and clinical applications in preci-
sion spine care can only be achieved via a more precision-based
approach fueled by an interdisciplinary platform of clinicians
and scientists symbiotically working together to facilitate
unprecedented discovery and innovation that can ultimately
develop tools to identify the right patients for the most appro-
priate intervention to obtain the best outcomes while simulta-
neously decreasing health care costs to all stakeholders for
global impact. A precision spine care approach reliant on big
data interconnecting numerous platforms of biometrics will be
key to realize such aspirations. As such, the onus to move the
spine field forward rests on the shoulders of all spine special-
ists, clinicians, and scientists alike. As a spine community, we
need to come together on a large-scale basis to address the
platform of precision spine care and its massive potential. It
is via collaboration and team work that we can elevate the
status quo of the spine discipline to new heights and make an
impact that will resonate for generations to come.
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